Charles River Labs Intl Stock
Price
Target price
€187.45
€187.45
-1.220%
-2.3
-1.220%
€249.59
02.07.24 / Tradegate
WKN: 939391 / Symbol: CRL / Name: Charles River Lb / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Charles River Labs Intl Stock
A loss of -1.220% shows a downward development for Charles River Labs Intl.
Charles River Labs Intl is currently one of the favorites of our community with 11 Buy predictions and no Sell predictions.
With a target price of 249 € there is a positive potential of 32.84% for Charles River Labs Intl compared to the current price of 187.45 €.
Pros and Cons of Charles River Labs Intl in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Charles River Labs Intl vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Charles River Labs Intl | -1.220% | -2.699% | -4.216% | -2.724% | -11.995% | -40.680% | - |
| Ironwood Pharmaceuticals | 5.220% | 4.310% | 4.310% | -37.629% | -40.686% | -43.458% | - |
| Novocure Ltd | -3.530% | -7.185% | -22.967% | -58.879% | 9.492% | -89.929% | - |
| Iovance Biotherapeutics Inc. | -4.160% | -8.664% | -12.189% | 11.542% | -7.915% | -67.801% | - |
Comments
Charles River Laboratories International, Inc. (NYSE: CRL) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $290.00 price target on the stock.
Show more
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International, Inc. (NYSE: CRL) had its price target lowered by analysts at Robert W. Baird from $282.00 to $270.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International, Inc. (NYSE: CRL) had its price target raised by analysts at Evercore ISI from $260.00 to $265.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CRL provided by MarketBeat
News
Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute at University of Colorado Anschutz Medical Campus
Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral vector contract development and
Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy
Charles River Laboratories International, Inc. (NYSE: CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a plasmid DNA and retrovirus vector
Charles River Laboratories, in Collaboration With MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a multidisciplinary program, funded through a $1.3 million grant from the Foundation for Chemistry Research & Initiatives